<DOC>
	<DOCNO>NCT00425711</DOCNO>
	<brief_summary>Acamprosate give approximately 30 DUI Court participants 3 month outcomes monitor . The hypothesis acamprosate safe well-tolerated subject ' crave symptom relate addiction improve time .</brief_summary>
	<brief_title>Study Acamprosate Driving Under Influence ( DUI ) Court Participants</brief_title>
	<detailed_description>Purpose : The study 13 week open-label study use acamprosate subject elect participate DUI Court program Tulsa County . Admission DUI Court completely voluntary . Participants must apply admission , undergo initial evaluation , receive approval District Attorney 's office presiding judge . The four-phase program require minimum 1 year complete . Each phase require counsel , mandatory random urine drug screen , mandatory daily breathalyzer test , nightly curfew participant gainfully employed school . Currently , approximately 10 % participant able complete program minimum 12 month requirement . The main objective study evaluate duration alcohol abstinence DUI Court participant receive acamprosate . Design : Thirty subject enrol study . New DUI court participant , within 3 month enrollment , invite participate trial . Qualified subject receive , addition require DUI court assessment treatment , physical examination , baseline safety laboratory , study drug , psychiatric evaluation , depressive anxiety rating scale , personality disorder questionnaire vital sign take visit . Alcohol substance use assess self-report validated review court-ordered laboratory breathalyzer test .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Acamprosate</mesh_term>
	<criteria>1 . Adult male females age 18 64 year age 2 . District Attorneyapproved DUI Court participant within 3 month enrollment DUI Court 3 . Currently meet DSMIV criterion alcohol dependence 4 . Subject agree alcohol abstinence goal 5 . Women must agree use approve method birth control ( tubal ligation , birth control pill , IUD ) 6 . Negative UCG ( female ) 7 . Treatment MAOI , antidepressant , antipsychotic , anticonvulsant , mood stabilizer , Saint John 's Wort permissible subject stable dose 3 month 8 . Must ability comprehend key component inform consent provide consent 9 . Current score 15 less Beck Depression Inventory II 10 . Subject undergone detoxification currently abstinent alcohol 1 . History allergy acamprosate 2 . Previously fail trial acamprosate 3 . Pregnancy , lactation , unprotected intercourse study period 4 . Lifetime diagnosis schizophrenia schizoaffective disorder 5 . Creatinine clearance &lt; 30 mL/minute . If serum creatinine great 1.4 mg/dL CockcroftGault equation use estimate creatinine clearance 6 . Active suicidality , Beck Depression Inventory II suicide item score &gt; 2 , Beck Depression Inventory II total score &gt; 15 7 . Any unstable medical condition , opinion investigator , consider clinically significant could affect subject 's safety ability complete study 8 . Use benzodiazepine sedativehypnotic agent ( include kava kava valerian ) , except eszopiclone , zaleplon , zolpidem &lt; 3 time weekly last 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Acamprosate</keyword>
	<keyword>Alcohol Dependence</keyword>
	<keyword>Driving Under Influence</keyword>
	<keyword>Drug Court</keyword>
	<keyword>DUI Court</keyword>
</DOC>